Since overexpression of the anti-apoptotic BCL-2 family members is observed in most patients with multiple myeloma [225], PP2A represents a target molecule to increase the effects of the autophagy modulators chemotherapeutic agents used for myeloma. This evidence concerns the gene BCL2 and plasma cell myeloma.